Granada: 28 May 2020 MEDINA, Almirall and UC3M to research new treatments for rare genetic diseases. Fundación MEDINA, Almirall, S.A. (ALM) and the University Carlos III Madrid (UC3M) have launched a project to find new treatments for recessive dystrophic...
MEDINA is leader in Drug Discovery from Microbial Natural Product Libraries and internal High Throughput Screening (HTS) programs are focused on strategic therapeutic areas: Infectious and Parasitic Diseases, Oncology and Neurodegeneration.
MEDINA, Almirall and UC3M to research new treatments for rare genetic diseases
Click on above image and keep up to date with our latest news.
MEDINA offers Contract Research services for Drug Discovery and other high value biotechnology areas to academic research and industrial organizations.
MEDINA discovers bio-active molecules, drug leads for unmet medical needs and high value biotechnological products.
We are exclusive owners of one of the world´s largest Microbial Collections (190,000 microbial strains), and Natural Products Libraries (over 135,000 extracts & fractions).
SUBSCRIBE TO OUR NEWSLETTER
MEDINA joins the global COVID-19 research effort looking for new therapeutics and diagnostic solutions for SARS-CoV-2.
MEDINA is a drug discovery organization and a partner site of the European research infrastructure EU-OPENSCREEN (www.eu-openscreen.eu). Leveraging our drug discovery expertise, the potential of our natural product libraries and the high throughput screening and...
New article by Fundacion MEDINA in collaboration with the Marine Biotechnology Department at the Stazione Zoologica Anton Dohrn, Naples, and the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences (ChiBioFarAm) of the University of Messina:...